Adriana A Jesus1, Alberto J S Duarte, João B Oliveira. 1. Pediatric Rheumatology Unit, Pediatrics Department, Universidade de São Paulo, Av. Dr. Enéas Carvalho de Aguiar 500 IMT Bldg. II 3rd floor, São Paulo, Sao Paulo 054030-000, Brazil.
Abstract
INTRODUCTION: Immunodeficiency with hyper-IgM (HIGM) results from genetic defects in the CD40-CD40 ligand (CD40L) pathway or in the enzymes required for immunoglobulin class switch recombination and somatic hypermutation. HIGM can thus be associated with an impairment of both B-cell and T-cell activation. RESULTS AND DISCUSSIONS: There are seven main subtypes of HIGM and the most frequent is X-linked HIGM, resulting from CD40L mutations. In addition to the susceptibility to recurrent and opportunistic infections, these patients are prone to autoimmune manifestations, especially hematologic abnormalities, arthritis, and inflammatory bowel disease. Furthermore, organ-specific autoantibodies are commonly found in HIGM patients. CONCLUSIONS: The mechanisms by which HIGM associates to autoimmunity are not completely elucidated but a defective development of regulatory T cells, the presence of IgM autoantibodies and an impaired peripheral B-cell tolerance checkpoint have been implicated. This article reviews the main subtypes of HIGM syndrome, the clinical autoimmune manifestations found in these patients, and the possible mechanisms that would explain this association.
INTRODUCTION:Immunodeficiency with hyper-IgM (HIGM) results from genetic defects in the CD40-CD40 ligand (CD40L) pathway or in the enzymes required for immunoglobulin class switch recombination and somatic hypermutation. HIGM can thus be associated with an impairment of both B-cell and T-cell activation. RESULTS AND DISCUSSIONS: There are seven main subtypes of HIGM and the most frequent is X-linked HIGM, resulting from CD40L mutations. In addition to the susceptibility to recurrent and opportunistic infections, these patients are prone to autoimmune manifestations, especially hematologic abnormalities, arthritis, and inflammatory bowel disease. Furthermore, organ-specific autoantibodies are commonly found in HIGMpatients. CONCLUSIONS: The mechanisms by which HIGM associates to autoimmunity are not completely elucidated but a defective development of regulatory T cells, the presence of IgM autoantibodies and an impaired peripheral B-cell tolerance checkpoint have been implicated. This article reviews the main subtypes of HIGM syndrome, the clinical autoimmune manifestations found in these patients, and the possible mechanisms that would explain this association.
Authors: S Lacroix-Desmazes; I Resnick; D Stahl; L Mouthon; T Espanol; J Levy; S V Kaveri; L Notarangelo; M Eibl; A Fischer; H Ochs; M D Kazatchkine Journal: J Immunol Date: 1999-05-01 Impact factor: 5.422
Authors: J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo Journal: J Pediatr Date: 1997-07 Impact factor: 4.406
Authors: P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy Journal: Cell Date: 2000-09-01 Impact factor: 41.582
Authors: Maxime Hervé; Isabelle Isnardi; Yen-shing Ng; James B Bussel; Hans D Ochs; Charlotte Cunningham-Rundles; Eric Meffre Journal: J Exp Med Date: 2007-06-11 Impact factor: 14.307
Authors: Andrea Cerutti; Montserrat Cols; Maurizio Gentile; Linda Cassis; Carolina M Barra; Bing He; Irene Puga; Kang Chen Journal: Ann N Y Acad Sci Date: 2011-11 Impact factor: 5.691
Authors: Mohamed-Ridha Barbouche; Qubo Chen; Marco Carbone; Imen Ben-Mustapha; Zakera Shums; Mehdi Trifa; Federica Malinverno; Francesca Bernuzzi; Haiyan Zhang; Nourhen Agrebi; Gary L Norman; Christopher Chang; M Eric Gershwin; Pietro Invernizzi Journal: Cell Mol Immunol Date: 2018-02-05 Impact factor: 11.530
Authors: Marc A Schwartz; Nikita S Kolhatkar; Chris Thouvenel; Socheath Khim; David J Rawlings Journal: J Immunol Date: 2014-08-29 Impact factor: 5.422